Spots Global Cancer Trial Database for claudin 18.2
Every month we try and update this database with for claudin 18.2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Early Access Program for Zolbetuximab | NCT06048081 | Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... | zolbetuximab | 18 Years - | Astellas Pharma Inc | |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | NCT06346392 | Gastric Cancer Gastroesophagea... | AZD0901 AZD0901 Ramucirumab+ pa... Paclitaxel Docetaxel Irinotecan TAS-102 Apatinib | 18 Years - 130 Years | AstraZeneca | |
| Early Access Program for Zolbetuximab | NCT06048081 | Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... | zolbetuximab | 18 Years - | Astellas Pharma Inc | |
| Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody | NCT05994001 | Biliary Tract C... Candonilimab Claudin 18.2 | cardonilizumab LM-302 | 18 Years - | Shanghai Zhongshan Hospital | |
| Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody | NCT05994001 | Biliary Tract C... Candonilimab Claudin 18.2 | cardonilizumab LM-302 | 18 Years - | Shanghai Zhongshan Hospital | |
| Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors | NCT04400383 | Solid Tumor Gastric Cancer Pancreatic Aden... | AB011 Injection | 18 Years - 80 Years | CARsgen Therapeutics Co., Ltd. | |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | NCT06219941 | Gastric Cancer Gastroesophagea... Pancreatic Aden... | AZD0901 5-Fluorouracil Leucovorin l-leucovorin Irinotecan Nanoliposomal I... Gemcitabine | 18 Years - | AstraZeneca | |
| Early Access Program for Zolbetuximab | NCT06048081 | Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... | zolbetuximab | 18 Years - | Astellas Pharma Inc | |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | NCT06219941 | Gastric Cancer Gastroesophagea... Pancreatic Aden... | AZD0901 5-Fluorouracil Leucovorin l-leucovorin Irinotecan Nanoliposomal I... Gemcitabine | 18 Years - | AstraZeneca | |
| A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer | NCT06396091 | Claudin 18.2 (C... | zolbetuximab mFOLFIRINOX | 18 Years - | Astellas Pharma Inc | |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | NCT06346392 | Gastric Cancer Gastroesophagea... | AZD0901 AZD0901 Ramucirumab+ pa... Paclitaxel Docetaxel Irinotecan TAS-102 Apatinib | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
